Teva Pharmaceutical Industries (TEVA) Profit After Tax (2016 - 2026)
Teva Pharmaceutical Industries (TEVA) posted Profit After Tax of $369.0 million for Q1 2026, down 21.99% on a QoQ basis from $473.0 million in Q4 2025, and up 72.43% year-over-year from $214.0 million in Q1 2025.
Teva Pharmaceutical Industries (TEVA) Profit After Tax (2016 - 2026) Analysis & Trends
Teva Pharmaceutical Industries' Profit After Tax history runs 11 years deep, the most recent figure standing at $369.0 million for Q1 2026.
- Quarterly Profit After Tax rose 72.43% year-over-year to $369.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 213.48% YoY) and the FY2025 annual result came in at $1.4 billion, up 171.98% from the prior year.
- Profit After Tax was $369.0 million for Q1 2026 at Teva Pharmaceutical Industries, down from $473.0 million in the prior quarter.
- Across five years, Profit After Tax topped out at $473.0 million in Q4 2025 and bottomed at -$1.3 billion in Q4 2022.
- A 5-year average of -$194.0 million and a median of -$253.0 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax plunged 1236.9% — and 2025, when it jumped 272.0%.
- Teva Pharmaceutical Industries' Profit After Tax stood at -$1.3 billion in 2022, then surged by 135.74% to $465.0 million in 2023, then tumbled by 159.14% to -$275.0 million in 2024, then soared by 272.0% to $473.0 million in 2025, then slipped by 21.99% to $369.0 million in 2026.
- Business Quant data shows TEVA's Profit After Tax at $369.0 million in Q1 2026, $473.0 million in Q4 2025, and $433.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 369.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -20.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 369.00 Mn |
| Dec 31, 2025 | 473.00 Mn |
| Sep 30, 2025 | 433.00 Mn |
| Jun 30, 2025 | 282.00 Mn |
| Mar 31, 2025 | 214.00 Mn |
| Dec 31, 2024 | -275.00 Mn |
| Sep 30, 2024 | -437.00 Mn |
| Jun 30, 2024 | -874.00 Mn |
| Mar 31, 2024 | -419.00 Mn |
| Dec 31, 2023 | 465.00 Mn |
| Sep 30, 2023 | 69.00 Mn |
| Jun 30, 2023 | -872.00 Mn |
| Mar 31, 2023 | -253.00 Mn |
| Dec 31, 2022 | -1.30 Bn |
| Sep 30, 2022 | 61.00 Mn |
| Jun 30, 2022 | -278.00 Mn |
| Mar 31, 2022 | -955.00 Mn |
| Dec 31, 2021 | -191.00 Mn |
| Sep 30, 2021 | 302.00 Mn |
| Jun 30, 2021 | 207.00 Mn |